Literature DB >> 12805448

Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge.

D Fischer1, D Rood, R W Barrette, A Zuwallack, E Kramer, F Brown, L K Silbart.   

Abstract

Guinea pigs immunized intranasally with a keyhole limpet hemocyanin-linked peptide, corresponding to the prominent G-H loop of the VP1 protein of foot-and-mouth disease virus, raised substantial levels of antipeptide and virus-neutralizing antibodies in sera and of peptide-specific secretory immunoglobulin A in nasal secretions. In groups of animals immunized intranasally without adjuvant, 86 percent were fully protected upon challenge with homotypic virus. Surprisingly, animals given the peptide conjugates plus the mucosal adjuvant cholera toxin were afforded only partial protection in that primary lesions were observed in most animals, although spread to other feet was prevented. These results indicate that intranasal inoculation with the peptide offers a potential route of vaccination against foot-and-mouth disease and may be useful for eliciting protection in the upper respiratory tracts of susceptible animals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805448      PMCID: PMC164810          DOI: 10.1128/jvi.77.13.7486-7491.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

2.  Functional analysis of T lymphocyte subsets in antiviral host defense.

Authors:  T P Leist; S P Cobbold; H Waldmann; M Aguet; R M Zinkernagel
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

3.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

Authors:  W E P Beyer; A M Palache; J C de Jong; A D M E Osterhaus
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

4.  Protection of cattle against foot-and-mouth disease by a synthetic peptide.

Authors:  R DiMarchi; G Brooke; C Gale; V Cracknell; T Doel; N Mowat
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

5.  Synthetic peptides in foot and mouth disease vaccine research.

Authors:  D J Rowlands
Journal:  Endeavour       Date:  1984       Impact factor: 0.444

6.  Opsonization-enhanced phagocytosis of foot-and-mouth disease virus.

Authors:  K C McCullough; D Parkinson; J R Crowther
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

7.  Effective synthetic peptide vaccine for foot-and-mouth disease in swine.

Authors:  Chang Yi Wang; Tseng Yuan Chang; Alan M Walfield; John Ye; Ming Shen; Shih Ping Chen; Ming Chang Li; Yeou Liang Lin; Ming Hwa Jong; Ping Cheng Yang; Nancy Chyr; Ed Kramer; Fred Brown
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

8.  Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.

Authors:  D Bessen; V A Fischetti
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

9.  Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.

Authors:  A B Hartman; L L Van De Verg; M M Venkatesan
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

10.  Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus.

Authors:  E Pfaff; M Mussgay; H O Böhm; G E Schulz; H Schaller
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more
  6 in total

1.  Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus.

Authors:  Steven M Szczepanek; Roger W Barrette; Debra Rood; Diana Alejo; Lawrence K Silbart
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

2.  Booster administration can make a difference in the antibody response to intradermal foot-and-mouth disease vaccination in cattle.

Authors:  Can Çokçalışkan; Pelin Tuncer-Göktuna; Beyhan Sareyyüpoğlu; Tunçer Türkoğlu; Muhammet Yıldız; M Nuri Fırat Deveci; Eylem Aras-Uzun; Abdullah Arslan; Ayça Kürkçü; Ergün Uzunlu; Erdoğan Asar
Journal:  Arch Virol       Date:  2022-01-16       Impact factor: 2.574

3.  An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.

Authors:  Hoyin Mok; Sharon J Tollefson; Amy B Podsiad; Bryan E Shepherd; Vasiliy V Polosukhin; Robert E Johnston; John V Williams; James E Crowe
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

4.  Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Authors:  Huiying Fan; Tiezhu Tong; Huanchun Chen; Aizhen Guo
Journal:  Virus Genes       Date:  2007-05-12       Impact factor: 2.332

5.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot-and-mouth disease peptide vaccines.

Authors:  Esther Blanco; Carolina Cubillos; Noelia Moreno; Juan Bárcena; Beatriz G de la Torre; David Andreu; Francisco Sobrino
Journal:  Clin Dev Immunol       Date:  2013-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.